Home LiteratureArticle Details
PMID: 15483292 Published · ppublish English Comment Letter

Bevacizumab in colorectal cancer.

The New England journal of medicine ·Vol. 351 ·No. 16 ·2004-10-14 ·Pages 1690-1; author reply 1690-1

Sonpavde G

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bevacizumab Colorectal Neoplasms/drug therapy Cross-Over Studies Disease Progression Humans Neoplasm Metastasis/drug therapy Randomized Controlled Trials as Topic/ethics Research Design
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Bevacizumab
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Sonpavde Guru
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJM200410143511622
Published
2004-10-14
Pages
1690-1; author reply 1690-1
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 15175435
External Links
PubMed source DOI: 10.1056/NEJM200410143511622 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2